RT Journal Article
SR Electronic
T1 A Territory-wide study of COVID-19 cases and clusters with unknown source in Hong Kong community: A clinical, epidemiological and phylogenomic investigation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.30.20045740
DO 10.1101/2020.03.30.20045740
A1 Leung, Kenneth Siu-Sing
A1 Ng, Timothy Ting-Leung
A1 Wu, Alan Ka-Lun
A1 Yau, Miranda Chong-Yee
A1 Lao, Hiu-Yin
A1 Choi, Ming-Pan
A1 Tam, Kingsley King-Gee
A1 Lee, Lam-Kwong
A1 Wong, Barry Kin-Chung
A1 Ho, Alex Yat-Man
A1 Yip, Kam-Tong
A1 Lung, Kwok-Cheung
A1 Liu, Raymond Wai-To
A1 Tso, Eugene Yuk-Keung
A1 Leung, Wai-Shing
A1 Chan, Man-Chun
A1 Ng, Yuk-Yung
A1 Sin, Kit-Man
A1 Fung, Kitty Sau-Chun
A1 Chau, Sandy Ka-Yee
A1 To, Wing-Kin
A1 Que, Tak-Lun
A1 Shum, David Ho-Keung
A1 Yip, Shea Ping
A1 Yam, Wing Cheong
A1 Siu, Gilman Kit-Hang
YR 2020
UL http://medrxiv.org/content/early/2020/03/31/2020.03.30.20045740.abstract
AB Background Initial cases of coronavirus disease 2019 (COVID-19) reported in Hong Kong were mostly imported cases from Mainland China. However, most cases reported in February 2020 were local infections with unknown source, indicating local community transmissions. This study aimed to report the clinical, epidemiological and phylogenomic characteristics of the local cases of COVID-19 in our community.Methods We extracted the demographic, clinical and epidemiological data from 50 COVID-19 patients, who accounted for 53·8% of the cases in Hong Kong by the end of February 2020. We used both Nanopore and Illumina platforms to perform whole-genome sequencing (WGS) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from these patients. Phylogenetic relatedness among these local cases and their placement in the global phylogeny were examined. The evolutionary rate and divergence time of transmission were also determined.Findings Of these 50 patients, only three (6·0%) had visited Wuhan while 43 (86·0%) did not have recent travel records. The average interval from symptom onset to hospital admission was 8·5 days. The most common signs and symptoms on admission were cough (74·0%) and fever (58·0%). Radiographic abnormality was found in 46 (92·0%) patients. Three (6·0%) patients required ICU admission. Phylogenetic analysis concurred with epidemiological investigation that 42 (84·0%) cases could be grouped into six transmission clusters. Forty-four (88·0%) cases harboured a common mutation Orf3a G251V. Global phylogeny of SARS-CoV-2 revealed that most (88·0%) cases in Hong Kong were clustered in two subclades with the strains from other countries. The estimated time to the most recent common ancestor (tMRCA) of COVID-2019 outbreak in Hong Kong was December 24, 2019 with an evolutionary rate of 3.04×10−3 substitutions per site per year. The reproduction number value was 1·84 as of February 28, 2020 in Hong Kong.Interpretation We provided a territory-wide overview of COVID-19 in Hong Kong, which has borders connecting to Mainland China. Transmission in closed settings especially during family and religious gatherings is a hallmark of the recently reported cases. The reproduction number value indicated an ongoing outbreak in the community. Rapid isolation of suspected or confirmed cases and their close contacts coupled with robust laboratory surveillance and social distancing is crucial to the containment of COVID-19 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was supported by internal funds from the Faculty of Health and Social Science, and Department of Health Technology and Informatics of The Hong Kong Polytechnic University.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the sequencing data (50 genomes of SARS-CoV-2) have been submitted to the GenBank with accession no. MT232662-MT232711.